安捷伦合作伙伴优必克斯治疗公司推进韩国的变革性癌症研究Agilent Partners Ubix Therapeutics to Advance Transformative Cancer Research in South Korea

动脉网2025-05-15

Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2535864116?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-15 14:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2535864116","market":"us","top_or_hot":-1,"title":"安捷伦合作伙伴优必克斯治疗公司推进韩国的变革性癌症研究Agilent Partners Ubix Therapeutics to Advance Transformative Cancer Research in South Korea","media":"动脉网","content":"<div>\n<p>Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515143219975a6005&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安捷伦合作伙伴优必克斯治疗公司推进韩国的变革性癌症研究Agilent Partners Ubix Therapeutics to Advance Transformative Cancer Research in South Korea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安捷伦合作伙伴优必克斯治疗公司推进韩国的变革性癌症研究Agilent Partners Ubix Therapeutics to Advance Transformative Cancer Research in South Korea\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-15 14:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515143219975a6005&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515143219975a6005&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2229751404.USD","symbol_name":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515143219975a6005&s=b","article_id":"2535864116","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515143219975a6005&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2535864116","pubTimestamp":1747290660,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding  with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South Korea over the next five years.安捷伦科技公司宣布最近与Ubix Therapeutics签署了一份谅解备忘录，将在未来五年内加速推进韩国高度靶向的癌症治疗研究与开发。Ubix Therapeutics首席执行官Seo Bo-Kwang评论道。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LENZ":"Therapeutics","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","BK4588":"碎股","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","BK4007":"制药","LU1543694498.USD":"法巴水资源基金RH MD Dis","BK4539":"次新股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","A":"安捷伦科技","BK4121":"生命科学工具和服务","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK4139":"生物科技"},"translate_title":"Agilent Partner Ubix Therapeutics Advances Transformative Cancer Research in Korea Agilent Partners Ubix Therapeutics to Advance Transformed Cancer Research in South Korea","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"A":0.9},"content_text":"Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South Korea over the next five years.安捷伦科技公司宣布最近与Ubix Therapeutics签署了一份谅解备忘录（MOU），将在未来五年内加速推进韩国高度靶向的癌症治疗研究与开发。Under this agreement, the two companies will conduct joint research to develop targeted protein degradation (TPD) and antibody-drug conjugate (ADC). This collaboration will combine Ubix’s proprietary Degraducer® anti-cancer drugs platform which features novel E3 ligase binders with Agilent’s cancer research and technology capabilities..根据该协议，两家公司将开展联合研究，以开发靶向蛋白降解（TPD）和抗体药物偶联物（ADC）。此次合作将结合Ubix专有的Degraducer®抗癌药物平台（具有新型E3连接酶结合剂）与安捷伦在癌症研究和技术方面的能力。Small molecule-induced TPD and ADC are rapidly emerging as a promising approach in precision oncology across the pharma and biopharma industries, with the global TPD market size estimated to reach US$4.37 billion by 2034¹. This novel method invites therapeutic potential in previously undruggable molecular spaces, paving the way to deliver safer and more effective answers for even the most difficult targets in ubiquitin proteasome pathway (UPP) and ligase complex..小分子诱导的TPD和ADC正在迅速成为制药和生物制药行业中精准肿瘤学领域的一种有前景的方法，预计到2034年，全球TPD市场规模将达到43.7亿美元¹。这种新颖的方法在以往无法成药的分子空间中展现了治疗潜力，为泛素-蛋白酶体途径（UPP）和连接酶复合物中即使是最困难的靶点，提供了更安全有效的解决方案。The collaboration leverages Agilent’s innovative technologies, such as InfinityLab Bio LC portfolio, LC/MS systems, and BioTek product families, developing efficient analytical methods and workflows to advance targeted cancer therapy and immuno-oncology research. This work supports Ubix in addressing the unmet needs of patients and increasing access to innovative novel treatments that may improve patient outcomes..该合作利用了安捷伦的创新技术，如InfinityLab Bio LC系列、LC/MS系统和BioTek产品家族，开发高效的分析方法和工作流程，以推动靶向癌症治疗和免疫肿瘤学研究。这项工作支持Ubix满足患者的未满足需求，并增加获得可能改善患者预后的创新新疗法的机会。“We are excited to collaborate with Agilent Technologies, whose leadership in biopharma and pharmaceutical innovation will strengthen Ubix Therapeutics’ efforts to deliver next-generation therapies. By leveraging Agilent’s advanced analytical and diagnostic platforms, we aim to accelerate development and bring transformation solutions to patients worldwide.” Commented Seo Bo-Kwang, CEO of Ubix Therapeutics, Inc. .“我们很高兴与安捷伦科技公司合作，他们在生物制药和医药创新领域的领导地位将加强Ubix Therapeutics开发下一代疗法的努力。通过利用安捷伦先进的分析和诊断平台，我们旨在加速开发并为全球患者带来变革性解决方案。” Ubix Therapeutics首席执行官Seo Bo-Kwang评论道。“We are proud to continue strengthening Agilent’s ongoing commitment to research, contributing to South Korea’s biomedical advancement and supporting our customer’s ambitious plan to bolster transformative cancer therapy globally. This partnership further demonstrates the confidence local companies place in our industry-leading scientific capabilities to bring great science to life.” said You Jae Soo, South Korea country general manager at Agilent..“我们很自豪能够继续加强安捷伦对研究的持续承诺，为韩国的生物医学发展做出贡献，并支持我们的客户在全球范围内推动变革性癌症治疗的宏伟计划。此次合作进一步证明了本地公司对我们行业领先的科学能力充满信心，能够将伟大的科学理念付诸实践。”安捷伦韩国国家总经理刘在洙表示。For more than 25 years, Agilent has been investing in South Korea and has since grown to approximately 400 skilled scientists, engineers, and employees. Housing a Centre of Excellence Analytical Lab in Seoul, the company has forged successful partnerships with local flagship universities, biomedical companies and start-ups.超过25年以来，安捷伦一直在韩国进行投资，目前已经发展到拥有大约400名熟练的科学家、工程师和员工。公司在首尔设有卓越中心分析实验室，并与当地顶尖大学、生物医学公司和初创企业建立了成功的合作关系。Most recently, Agilent partnered with GI Innovation for biomarker testing of immune-anticancer drug GI-101 and Theragen Bio to advance bioinformatic solutions for cancer genomic profiling..最近，安捷伦与GI Innovation合作进行免疫抗癌药物GI-101的生物标志物检测，并与Theragen Bio合作推进用于癌症基因组分析的生物信息学解决方案。About Ubix Therapeutics关于Ubix TherapeuticsUbix Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to transforming medicine by leveraging targeted protein degradation (TPD) to address unmet medical needs in oncology. With a commitment to scientific excellence and innovation, Ubix is developing a robust pipeline of first-in-class drug candidates, including BTK/HCK/LYN degrader in phase 1 clinical trial for treatment of B cell malignancies and SHP2 degrader for treatment of KRAS-driven solid tumors in preclinical development.Ubix Therapeutics, Inc. 是一家临床阶段的生物技术公司，致力于通过利用靶向蛋白降解 (TPD) 来满足肿瘤学中未被满足的医疗需求，从而变革医学。凭借对科学卓越和创新的承诺，Ubix 正在开发一系列强大的首创候选药物，其中包括处于一期临床试验、用于治疗B细胞恶性肿瘤的BTK/HCK/LYN降解剂，以及处于临床前开发阶段、用于治疗KRAS驱动实体瘤的SHP2降解剂。The company is also developing innovative new modality such as Degrader-Antibody Conjugate (DAC). For more information, please visit www.ubixtrx.com..该公司还正在开发创新的新模式，例如降解剂-抗体偶联物 (DAC)。欲了解更多信息，请访问 www.ubixtrx.com。About Agilent Technologies关于安捷伦科技Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions.安捷伦科技有限公司（纽约证券交易所代码：A）是分析和临床实验室技术的全球领导者，提供洞察力和创新，帮助客户实现卓越的科学成果。安捷伦全方位的解决方案包括仪器、软件、服务和专业知识，为客户提供可信赖的答案，解决他们最具挑战性的问题。The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. .该公司在2024财年创造了65.1亿美元的收入，并在全球范围内雇佣了大约18,000名员工。有关安捷伦的信息可访问www.agilent.com。如需获取最新的安捷伦新闻，请订阅安捷伦新闻中心。Source: agilent.com来源：agilent.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535864116","isCrawlerRequest":true}